Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M. Brunner(Massachusetts General Hospital), Amir T. Fathi(Massachusetts General Hospital)The Lancet HaematologyDecember 11, 201910.1016/s2352-3026(19)30203-0Cited by 30SaveCiteExport RISWatch citationsRelated PapersPhase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia|Haematologica|2016|43